News

Advanced Therapies,Clinical & Regulatory,Genomics and sequencing,Research & Development,Therapeutic Areas
Skylark Bio doses first patient in Phase 1/2 trial for GJB2-related deafness
read more
Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development
CellProthera and Alfresa sign MOU for ProtheraCytes Phase 3 trial in Japan
read more
Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas
FDA approves Moderna’s mRNA flu vaccine mFLUSIVA
read more
Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
Vaderis raises $152M and starts Phase 3 trial of engasertib in HHT
read more
Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
AC Immune gets FDA Fast Track for Parkinson’s immunotherapy ACI-7104
read more
Biotech & Pharma Business,Digital & Data,Genomics and sequencing,Research & Development,Therapeutic Areas
Bios Life launches with $25M funding and Tempus cancer AI partnership
read more
Drug Delivery & Formulation,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
Calla Lily selected for $50M Wellcome Leap antibiotic programme
read more
Advanced Therapies,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
Oncoinvent publishes Radspherin dosimetry data in Journal of Nuclear Medicine
read more
Central Nervous System,Genomics and sequencing,Research & Development,Therapeutic Areas
Alamar expands Alzheimer’s proteomics partnership with 86,000 more samples
read more
Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Digital & Data,Medical devices
OSF HealthCare expands RapidAI clinical AI platform to all 18 hospitals
read more
Central Nervous System,Clinical & Regulatory,Research & Development,Therapeutic Areas
Zilucoplan accepted for eligible myasthenia gravis patients in NHS Scotland
read more
Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics
FDA issues Complete Response Letter for ITM-11 over manufacturing issues
read more
Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development
Grifols completes Phase 3 SPARTA study of Prolastin-C in alpha-1 emphysema
read more
Digital & Data,Drug Discovery & Development,Research & Development
Novo Nordisk and AWS launch London AI hub to accelerate drug discovery
read more
Clinical & Regulatory
Acarizax accepted for house dust mite allergy treatment in NHS Scotland
read more
Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
Almirall and CrystalO partner on small-molecule drug discovery in dermatology
read more

Skylark Bio doses first patient in Phase 1/2 trial for GJB2-related deafness

CellProthera and Alfresa sign MOU for ProtheraCytes Phase 3 trial in Japan

FDA approves Moderna’s mRNA flu vaccine mFLUSIVA

Vaderis raises $152M and starts Phase 3 trial of engasertib in HHT

AC Immune gets FDA Fast Track for Parkinson’s immunotherapy ACI-7104

Bios Life launches with $25M funding and Tempus cancer AI partnership

Calla Lily selected for $50M Wellcome Leap antibiotic programme

Oncoinvent publishes Radspherin dosimetry data in Journal of Nuclear Medicine

Alamar expands Alzheimer’s proteomics partnership with 86,000 more samples

OSF HealthCare expands RapidAI clinical AI platform to all 18 hospitals

Zilucoplan accepted for eligible myasthenia gravis patients in NHS Scotland

FDA issues Complete Response Letter for ITM-11 over manufacturing issues

Grifols completes Phase 3 SPARTA study of Prolastin-C in alpha-1 emphysema

Novo Nordisk and AWS launch London AI hub to accelerate drug discovery

Acarizax accepted for house dust mite allergy treatment in NHS Scotland

Almirall and CrystalO partner on small-molecule drug discovery in dermatology

main menu

recent posts

EURneffy recommended for emergency anaphylaxis treatment in NHS Wales

Lifebit awarded three-year NIHR BioResource research environment contract

Resolution Therapeutics partners with Blood Centers of America for RTX001 programme

get connected